United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study
02/03/2026 11:35
March 2 (Reuters) - United Therapeutics UTHR.O said on Monday its experimental pill for a type of blood pressure disorder met all the main and secondary goals of a late-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug